Empowering health.
Our Technology Adjuvance Technologies has developed the ability to synthesize saponin adjuvants such as QS-21, a critical component of the…
Adjuvance Technologies announced today that it has been awarded supplemental contract funding from The National Institute of Allergy and Infectious…
- Adjuvance Technologies announced today that it has received a $20 million Series A investment from Morningside Venture Investments Limited.…
In a preclinical model, GSK scientists report a greater immune response to GSK Shingles vaccine (Hz/su) formulations that contain QS-21.
Adjuvance Technologies 1225 L Street, Suite 600 Lincoln, NE 68508 Phone: 402-817-5050
